Inducing analgesia by implantation of cells releasing neuroactive substances

• US 4,753,635 A
• Filed: 05/23/1986
• Issued: 06/28/1988
• Est. Priority Date: 05/23/1986
• Status: Expired due to Fees

• Current Assignee: Cytotherapeutics, Inc.
• Original Assignee: George D. Pappas, Harvey B. Pollard, Jacqueline Sagen, Mark Perlow
• Inventors: Perlow, Mark, Pollard, Harvey B., Sagen, Jacqueline, Pappas, George D.
• Primary Examiner(s): Rosenbaum, C. Fred
• Assistant Examiner(s): Rose, Sharon
• Application Number:
  US06/866,479
• Time in Patent Office: 767 Days
• Field of Search: 128/1 R, 604/890-891, 604/31, 604/48-50, 514/809, 514/816-818, 514/21, 435/244-245
• US Class Current: 604/522
• CPC Class Codes: A61F 2/02 Prostheses implantable into the body closure means for urethra or rectum or for artificial body openings therefor A61F2/0004
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Abstract

A method of inducing analgesia or reducing pain is described. The method involves implanting in the central nervous system of a host susceptible to pain, living material capable of releasing effective amount of analgesic substance when interacted with a stimulus which induces said material to release analgesic amount of said substance. The procedure described herein reduces sensitivity to intractable pain.

Claims

1. A method of inducing analgesia or reducing pain comprising implanting isolated, substantially homogeneously purified chromaffin cells or adrenal medullary tissue in nociceptor region of central nervous system of a host susceptible to pain, and stimulating said cells or tissue by infecting a nicotinic or muscarinic agonist to release effective amount of analgesic substance to reduce pain.

2. The method of claim 1 wherein said material is isolated, substantially homogeneously purified bovine chromaffin cells.

3. The method of claim 2, wherein said nociceptor region is in spinal cord or brain stem.

4. The method of claim 1 wherein said stimulus is nicotine.

5. The method according to claim 1, of reversing the release of analgesic substance by an antagonist.

6. The method of claim 5 wherein said antagonist is selected from the group consisting of opiate antagonist, adrenergic antagonist and ganglionic antagonist.

7. The method of claim 6 wherein said antagonist is naloxone.

8. The method of claim 3, wherein the nociceptor region in the spinal cord is dorsal horn of lumbar region.

9. The method of claim 8, wherein the nociceptor region in the spinal cord is subarachnoid space of dorsal horn of lumbar region.

10. The method of claim 3, wherein the nociceptor region in the spinal cord is substantia gelatinosa.

11. The method of claim 3, wherein the nociceptor region in the brain stem is selected from the group consisting of peraqueductal gray, nucleous raphe magnus and nucleus reticularis gigantocellularis.

12. The method of claim 11, wherein the nociceptor region is periaqueductal gray.

13. The method of claim 11, wherein the nociceptor region is nucleus raphe magnus.

14. The method of claim 11, wherein the nociceptor region is nucleus reticularis giganticellularis.